You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Mallinckrodt
Johnson and Johnson
Dow
Express Scripts

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

SANDOSTATIN LAR Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Sandostatin Lar, and what generic alternatives are available?

Sandostatin Lar is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in SANDOSTATIN LAR is octreotide acetate. There are twenty drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the octreotide acetate profile page.

US ANDA Litigation and Generic Entry Outlook for Sandostatin Lar

A generic version of SANDOSTATIN LAR was approved as octreotide acetate by WEST-WARD PHARMS INT on April 8th, 2005.

  Start Trial

Drug patent expirations by year for SANDOSTATIN LAR
Drug Prices for SANDOSTATIN LAR

See drug prices for SANDOSTATIN LAR

Recent Clinical Trials for SANDOSTATIN LAR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NeuroEndocrine Tumor Research Foundation (NETRF)Phase 1
Roswell Park Cancer InstitutePhase 1
Ono Pharmaceutical Co. LtdPhase 1

See all SANDOSTATIN LAR clinical trials

US Patents and Regulatory Information for SANDOSTATIN LAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-001 Nov 25, 1998 RX Yes No   Start Trial   Start Trial   Start Trial
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-002 Nov 25, 1998 RX Yes No   Start Trial   Start Trial   Start Trial
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-003 Nov 25, 1998 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SANDOSTATIN LAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-002 Nov 25, 1998   Start Trial   Start Trial
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-003 Nov 25, 1998   Start Trial   Start Trial
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-002 Nov 25, 1998   Start Trial   Start Trial
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-003 Nov 25, 1998   Start Trial   Start Trial
Novartis SANDOSTATIN LAR octreotide acetate INJECTABLE;INJECTION 021008-001 Nov 25, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Dow
McKinsey
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.